Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tahir Effendi

Internal Medicine Watervliet, NY Medical Doctor

NPI 1285739789 CMS profile 149425

1500 2Nd Ave, Watervliet, NY 12189

Open in the dashboard

General payments

$16,178

349 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$31,920 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Tahir Effendi of Watervliet, NY is reported in the CMS Open Payments database as having received $16,178 across 349 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $31,920 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,987 59
2024 General $955 48
2023 General $613 32
2022 General $547 30
2021 General $738 56
2020 General $355 31
2019 General $982 93

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tahir Effendi
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Tahir Effendi were reported at $11,987. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Tahir Effendi Internal Medicine median Middle half National median
2019 $982 $159 $48–$570 $163
2020 $355 $119 $33–$402 $114
2021 $738 $135 $37–$521 $132
2022 $547 $141 $42–$496 $149
2023 $613 $149 $45–$519 $160
2024 $955 $154 $47–$537 $164
2025 $11,987 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Renalytix AI, Inc. $11,054 16 payments
  2. GlaxoSmithKline, LLC. $1,014 60 payments
  3. Novo Nordisk Inc $821 40 payments
  4. Janssen Pharmaceuticals, Inc $509 79 payments
  5. AbbVie, Inc. $423 22 payments
  6. AstraZeneca Pharmaceuticals LP $413 27 payments
  7. Dexcom, Inc. $242 12 payments
  8. Lilly USA, LLC $235 10 payments
  9. Abbott Laboratories $184 10 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $144 7 payments
  11. Other $1,139 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $10,880 2 payments
  2. Food and Beverage $5,292 346 payments
  3. Education $5 1 payment
Products named General payments · program years 2019–2025
  1. KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT $11,054 16 payments
  2. TRELEGY ELLIPTA $812 49 payments
  3. XARELTO $460 68 payments
  4. Ozempic $437 20 payments
  5. RYBELSUS $304 14 payments
  6. INVOKANA $272 49 payments
  7. FARXIGA $233 15 payments
  8. Dexcom G6 Transmitter $230 11 payments
  9. VRAYLAR $208 11 payments
  10. MOUNJARO $203 9 payments
  11. Other $3,024 171 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 108 drugs

Part D claims

5,520

Median for Internal Medicine: 777

Drug cost

$988,199

Median for Internal Medicine: $73,373

Branded share of claims

25.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 126 $197,017
Jardiance Empagliflozin Brand 135 $176,067
Farxiga Dapagliflozin Propanediol Brand 137 $151,258
Trulicity Dulaglutide Brand 87 $131,332
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 78 $47,635
Rybelsus Semaglutide Brand 20 $35,632
Tradjenta Linagliptin Brand 37 $33,227
Eliquis Apixaban Brand 32 $31,096
Januvia Sitagliptin Phosphate Brand 21 $30,265
Mounjaro Tirzepatide Brand 11 $19,814

The 10 drugs with the highest cost, of 108 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$62,065

Of which drugs: $4,707

Medicare patients

154

Average age 71

Services billed

1,023

82 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 49%
Chronic kidney disease 42%
Ischemic heart disease 34%
Arthritis 30%
Depression 20%
COPD 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 60 60 $4,266

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Ozempic
  • Novo Nordisk Inc $128
$128 126 —
Wegovy
  • Novo Nordisk Inc $82
$82 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $67
$67 78 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $34
  • Lilly USA, LLC $31
$66 135 —
MOUNJARO
  • Lilly USA, LLC $63
$63 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

349 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record